What is the management approach for a gout flare using Kenalog (triamcinolone) and Toradol (ketorolac)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For managing a gout flare, a combination of Kenalog (triamcinolone) and Toradol (ketorolac) can be effective, as supported by the 2020 American College of Rheumatology guideline for the management of gout 1.

Management Approach

The management approach for a gout flare using Kenalog (triamcinolone) and Toradol (ketorolac) involves:

  • A single intramuscular injection of Kenalog 40mg along with Toradol 60mg IM for rapid relief
  • Alternatively, Kenalog can be injected directly into the affected joint at a dose of 10-40mg depending on joint size
  • Toradol can be given as 30-60mg IM or 10mg orally every 4-6 hours for up to 5 days

Rationale

This combination works well because triamcinolone reduces inflammation through corticosteroid action, while ketorolac provides immediate pain relief through its NSAID properties.

Monitoring and Precautions

Patients should be monitored for potential side effects including:

  • Elevated blood glucose (particularly in diabetics)
  • Gastrointestinal irritation
  • Renal effects

Accompanying Measures

This approach should be accompanied by:

  • Rest
  • Ice application
  • Joint elevation
  • Increased fluid intake

Long-term Management

For long-term management, patients should be started on allopurinol or febuxostat after the acute flare resolves to prevent future attacks by lowering uric acid levels, as recommended by the American College of Physicians 1.

Lifestyle Modifications

Patients with recurrent gout should also be counseled on lifestyle modifications including:

  • Weight loss
  • Limiting alcohol intake
  • Avoiding purine-rich foods, as suggested by the 2016 updated EULAR evidence-based recommendations for the management of gout 1.

From the Research

Management Approach for Gout Flare

The management approach for a gout flare using Kenalog (triamcinolone) and Toradol (ketorolac) involves the following:

  • Kenalog (triamcinolone) is a corticosteroid that can be used to treat acute gout flares, especially in patients who cannot tolerate non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine 2, 3.
  • Toradol (ketorolac) is an NSAID that can be used to treat acute gout flares, but its use should be limited to a short duration and in low doses due to the risk of adverse events 2, 3.
  • The use of corticosteroids, such as Kenalog, may be considered in patients with acute gout flares who have contraindications to NSAIDs or colchicine, or in those who have failed to respond to these treatments 4.
  • Prophylaxis for acute gout flares after initiation of urate-lowering therapy can be achieved with low-dose colchicine or low-dose NSAIDs, such as naproxen, for up to 6 months 5.

Treatment Options

Treatment options for acute gout flares include:

  • Non-steroidal anti-inflammatory drugs (NSAIDs), such as Toradol (ketorolac) 2, 3
  • Colchicine 2, 4
  • Corticosteroids, such as Kenalog (triamcinolone) 2, 3, 4
  • Interleukin-1 inhibitors, such as canakinumab and rilonacept 6

Considerations

Considerations for the management of gout flares include:

  • Patient comorbidities, such as cardiovascular disease or renal impairment, which may affect treatment choices 3
  • Potential drug interactions and side effects, such as gastrointestinal toxicity with NSAIDs or corticosteroids 2, 3
  • The need for prophylaxis to prevent acute gout flares after initiation of urate-lowering therapy 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical manifestations of gout and their management.

The Medical journal of Australia, 2000

Research

Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020

Research

[Treatment of gout].

La Revue de medecine interne, 2011

Research

Interleukin-1 inhibitors for acute gout.

The Cochrane database of systematic reviews, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.